O-RAN ALLIANCE Announces Cooperation with ATIS, Activities at MWC Barcelona 2023, 7th Release of Open Software and New OTICs
19.1.2023 01:59:00 EET | Business Wire | Press release
New MoU between O-RAN ALLIANCE and ATIS opens the opportunity for ATIS adopting O-RAN specifications
O-RAN ALLIANCE and ATIS signed a Memorandum of Understanding to further both organizations’ mutual objectives to advance the industry towards more intelligent, open, virtualized and global standards-compliant Radio Access Networks (RAN).
“O-RAN is welcoming the opportunity to work with ATIS,” said Alex Jinsung Choi, Chairman of the O-RAN ALLIANCE and SVP Group Technology at Deutsche Telekom. “We look forward to the opportunity to consider ATIS adopting O-RAN specifications for ATIS Open RAN standards and working together to define the next generation of open and intelligent RAN technology.”
O-RAN ALLIANCE event and demos at MWC Barcelona to bring latest updates from the open RAN ecosystem
O-RAN ALLIANCE plans to hold its next industry event on February 28, 2023 from 15:30-16:30 CET at MWC Barcelona 2023, hosted by Deutsche Telekom at Hall 3 Stand 3M31. The event will include:
- Keynotes by Alex Jinsung Choi, Chairman of the O-RAN ALLIANCE and Stefan Engel-Flechsig, O-RAN ALLIANCE’s COO
- Views on open RAN testing & integration and security by CSPs from Asia, Europe and Americas
- Industry panel discussions on regional development (deployments and trials), security, ecosystem maturity and energy efficiency by key CSPs and vendors from the O-RAN ecosystem
Follow our website for speaker lineup and further updates.
More than 60 O-RAN member companies plan to present demonstrations of their O-RAN based technology and solutions at MWC Barcelona or the O-RAN Virtual Exhibition and welcome visitors to join their booths. O-RAN ALLIANCE plans to issue a map of the demos at the exhibition. Follow us on the O-RAN ALLIANCE LinkedIn channel to learn more, closer to the event.
O-RAN Software Community 7th release “G” expanded to 13 project streams
In December 2022, following on the half year release cycle, the O-RAN Software Community (OSC) published its 7th open software release named "G". For the G release, the OSC expanded to 13 project streams, adding a new AI/ML Framework project.
With each release, OSC’s open software continues to greatly help companies to develop, test and integrate their commercial open and intelligent RAN solutions. Contributions to OSC’s open software come from a diverse community, delivering a broad scope of software according to latest O-RAN ALLIANCE specifications.
"I am so delighted to see the 7th release and the addition of the new AI/ML Framework project stream from our open source community," said Chih-Lin I, Chief Scientist from China Mobile and Co-chair of O-RAN Technical Steering Committee. "With O-RAN ALLIANCE moving into its 5th year, we look forward to evolving towards a new phase. I deeply believe that the power of open source is essential in pushing O-RAN's progress to new heights in the coming years."
“The growth of the O-RAN Software Community has been tremendous. With the O-RAN SC G release, this milestone will help further accelerate O-RAN globally and advance the deployment of flexible networks demanding carrier-grade cloud-native infrastructure as we move towards an intelligent systems world fueled by innovative edge applications,” said Gil Hellmann, vice president, Telecom Solutions Engineering, Wind River. “For the latest O-RAN SC G release, Wind River has continued to provide key contributions to the INF project by working with the community to enable more Open RAN related features in StarlingX and implementing a framework supporting the latest published O2 interface, which is pivotal to cloud infrastructure management and deployment operations. We look forward to continuing our close collaboration.”
New Open Testing and Integration Centres (OTIC) approved in Japan and North America
O-RAN ALLIANCE is pleased to announce Japan OTIC and North American OTIC in NYC Metro Area/East (COSMOS) joining the community of Open Testing and Integration Centres. With this addition there are now 9 approved OTICs across Europe, the Americas and Asia.
“Shared testing and integration are key to delivering commercial O-RAN solutions, so it is great to see more OTICs being approved in North America and around the world,” said Igal Elbaz, Network CTO of AT&T and Board member of O-RAN ALLIANCE. “OTICs are also part of O-RAN PlugFests and the O-RAN Certification and Badging program, promoting more confidence in O-RAN products, components, and solutions within the industry.”
"We are delighted with the start of Japan OTIC, pinned by the opening ceremony last month, and believe the neutral and open testing environment for vendors will help to advance O-RAN solutions," said Naoki Tani, EVP and CTO at NTT DOCOMO and Board member of O-RAN ALLIANCE. "NTT DOCOMO has deployed 5G networks nationwide with O-RAN compliant equipment and intends to further expand the O-RAN ecosystem as co-host of Japan OTIC together with YRP R&D Promotion Committee and Japanese operators.”
For more about O-RAN ALLIANCE testing and integration efforts and the OTICs, please visit our website.
About O-RAN ALLIANCE
The O-RAN ALLIANCE is a world-wide community of more than 300 mobile operators, vendors, and research & academic institutions operating in the Radio Access Network (RAN) industry. As the RAN is an essential part of any mobile network, the O-RAN ALLIANCE’s mission is to re-shape the industry towards more intelligent, open, virtualized and fully interoperable mobile networks. The new O-RAN specifications enable a more competitive and vibrant RAN supplier ecosystem with faster innovation to improve user experience. O-RAN based mobile networks at the same time improve the efficiency of RAN deployments as well as operations by mobile operators. To achieve this, the O-RAN ALLIANCE publishes new RAN specifications, releases open software for the RAN, and supports its members in integration and testing of their implementations.
For more information, please visit www.o-ran.org.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230118005984/en/
Contact information
O-RAN ALLIANCE PR Contact
Zbynek Dalecky
pr@o-ran.org
O-RAN ALLIANCE e.V.
Buschkauler Weg 27
53347 Alfter/Germany
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Bending Spoons S.p.A. announces pricing of initial public offering1.7.2026 02:56:00 EEST | Press release
Bending Spoons S.p.A. (“Bending Spoons”), a leading technology company, today announces the pricing of its initial public offering (“IPO”) at $29.00 per share. A total of 57,971,015 ordinary shares are being offered, of which 34,398,640 shares are being offered by Bending Spoons and 23,572,375 shares are being offered by certain selling shareholders (the “Selling Shareholders”). Bending Spoons will not receive any proceeds from any sale of shares by the Selling Shareholders. The shares are expected to begin trading on the Nasdaq Global Select Market under the ticker symbol “BSP” on July 1, 2026. The offering is expected to close on July 2, 2026, subject to customary closing conditions. In addition, Bending Spoons and the Selling Shareholders granted the underwriters an option to purchase up to an additional 5,244,026 ordinary shares from Bending Spoons and up to an additional 3,451,626 ordinary shares from the Selling Shareholders at the initial public offering price, less underwriting
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 19:19:00 EEST | Press release
Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease and lung cancer,” she added. “More broadly, it reinforces the agency’s science-based approach to evaluating products across the co
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 18:00:00 EEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 17:13:00 EEST | Press release
For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and more practical: what it takes to make a specific, high-stakes determination reliable, fast and affordable at scale. A vertical, domain-focused process, gro
Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 17:08:00 EEST | Press release
Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom